ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares [Yahoo! Finance]
Oric Pharmaceuticals, Inc. (ORIC)
Company Research
Source: Yahoo! Finance
6, 2024, according to a recent SEC Filing . The transaction was executed at an average price, resulting in a total value of the sale being undisclosed. Warning! GuruFocus has detected 4 Warning Signs with ORIC. ORIC Pharmaceuticals Inc is a biopharmaceutical company dedicated to discovering, developing, and commercializing oncology-based therapies. The company's focus is on addressing mechanisms of therapeutic resistance in cancer patients, and it operates primarily within the biotechnology and drug industries. Over the past year, the insider has sold a total of 134,539 shares of ORIC Pharmaceuticals Inc and has not made any purchases of the stock. The recent sale by Jacob Chacko is part of a series of insider transactions that have taken place at the company. In the past year, there have been 8 insider sells and no insider buys. On the day of the insider's recent sale, shares of ORIC Pharmaceuticals Inc were trading at $16.21. The company's market capitalization stood at appr
Show less
Read more
Impact Snapshot
Event Time:
ORIC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORIC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORIC alerts
High impacting Oric Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ORIC
News
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC [Yahoo! Finance]Yahoo! Finance
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLCGlobeNewswire
- ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswire
ORIC
Earnings
- 11/6/23 - Beat
ORIC
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- ORIC's page on the SEC website